Long-term outcomes and complications in cancer patients who have recovered from COVID-19

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

ESMO President: What to watch for at ESMO 2021

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma

OncoAlert and ecancer - ESMO 2021 preview

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Should every transplant eligible NDMM patient receive a transplant?

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy